EUVIMEDEUVIMED entdecken
Crossref

Outcomes of treatment for deep left ventricular assist device infection

Michael T Simpson, Yuming Ning, Paul Kurlansky, Paolo C Colombo, Melana Yuzefpolskaya, Nir Uriel, Yoshifumi Naka, Koji Takeda

The Journal of Thoracic and Cardiovascular Surgery · 2024-05 · 167 (5) · 1824-1832.e2

DOI: 10.1016/j.jtcvs.2022.09.020 ↗

Kurz gefasst

Fachartikel in der Zeitschrift The Journal of Thoracic and Cardiovascular Surgery, 2024-05. Verfasst von Michael T Simpson und 7 weiteren Autor:innen. Beteiligte Einrichtung: Division of Cardiothoracic and Vascular Surgery, New York Presbyterian Hospital, Columbia University Medical Center, New York, NY. Hauptthemen laut MEDLINE: Heart Failure, Heart-Assist Devices, Methicillin-Resistant Staphylococcus aureus, Heart Transplantation. Die Arbeit wurde bisher 6-mal zitiert (Crossref) und nennt 21 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

OBJECTIVE: Among left ventricular assist device patients, the most commonly infected component is the drive line, which can be managed with antibiotics and local debridement. Infection of intrathoracic device components is less common but more difficult to manage. Herein we describe the incidence of deep device infection (DDI) at our center as well as management and outcomes. METHODS: We retrospectively reviewed 658 patients who underwent implantable left ventricular assist device insertion with HeartMate 2 (Abbott) or HeartMate 3 (Abbott) devices between January 2004 and June 2021. DDI was defined according to radiographic and clinical criteria. Cumulative incidence was calculated using a Fine-Gray subdistribution model; survival analysis was performed using the method of Kaplan and Meier. RESULTS: There were 32 (4.8%) DDIs during this study period. Drive line infection and re-exploration for bleeding were associated with development of DDI. Cumulative incidence of DDI increased over time, affecting 11% (7%-18%) at 5 years. The dominant microbes involved in DDI were Pseudomonas aeruginosa (19%) and methicillin-resistant Staphylococcus aureus (13%). Nineteen patients (59%) with device infection underwent device exchange, 6 (19%) underwent initial transplant, and 7 (22%) were treated solely with debridement and antibiotics. Of those who underwent device exchange, 12 (63%) developed reinfection of their new device and 6 underwent subsequent heart transplant. Patients who underwent transplantation for management of device infection had improved 5-year survival (80% vs 11%; P = .01) but 3 patients (25%) developed deep sternal wound infection after transplant. CONCLUSIONS: DDI is a rare but challenging complication in this destination era. Heart transplantation is the preferred management strategy for eligible patients but infectious complication is common.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Heart FailureHeart-Assist DevicesMethicillin-Resistant Staphylococcus aureusHeart TransplantationHumansRetrospective StudiesTreatment OutcomeAnti-Bacterial Agents

Stichwörter der Autor:innen

LVADdeep LVAD infectiondevice exchangeheart transplant

Substanzen

Anti-Bacterial Agents

Autor:innen und Institutionen

  • Division of Cardiothoracic and Vascular Surgery, New York Presbyterian Hospital, Columbia University Medical Center, New York, NY.
  • Center for Innovation and Outcomes Research, New York Presbyterian Hospital, Columbia University Medical Center, New York, NY.
  • Division of Cardiology, Department of Medicine, New York Presbyterian Hospital, Columbia University Medical Center, New York, NY.
  • Department of Cardiothoracic Surgery, New York Presbyterian Hospital, Weill Cornell Medical Center, New York, NY.
  • Division of Cardiothoracic and Vascular Surgery, New York Presbyterian Hospital, Columbia University Medical Center, New York, NY. Electronic address: kt2485@cumc.columbia.edu.

Zitieren

APA

Simpson, M. T., Ning, Y., Kurlansky, P., Colombo, P. C., Yuzefpolskaya, M., Uriel, N., Naka, Y., & Takeda, K. (2024). Outcomes of treatment for deep left ventricular assist device infection. The Journal of Thoracic and Cardiovascular Surgery, 167(5), 1824-1832.e2. https://doi.org/10.1016/j.jtcvs.2022.09.020

Vancouver

Simpson MT, Ning Y, Kurlansky P, Colombo PC, Yuzefpolskaya M, Uriel N, et al. Outcomes of treatment for deep left ventricular assist device infection. The Journal of Thoracic and Cardiovascular Surgery. 2024;167(5):1824-1832.e2. doi:10.1016/j.jtcvs.2022.09.020

BibTeX
@article{Simpson2024,
  author = {Simpson, Michael T and Ning, Yuming and Kurlansky, Paul and Colombo, Paolo C and Yuzefpolskaya, Melana and Uriel, Nir and Naka, Yoshifumi and Takeda, Koji},
  title = {Outcomes of treatment for deep left ventricular assist device infection},
  journal = {The Journal of Thoracic and Cardiovascular Surgery},
  year = {2024},
  volume = {167},
  number = {5},
  pages = {1824--1832.e2},
  doi = {10.1016/j.jtcvs.2022.09.020}
}
Kostenlos starten →